Advertisement


Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

2017 Gastrointestinal Cancers Symposium

Advertisement

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).



Related Videos

Colorectal Cancer

Michael J. Overman, MD, on Colorectal Cancer: Updated Results From CheckMate 142

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).

Colorectal Cancer

Cynthia L. Sears, MD, on Colon Cancer: Keynote Lecture

Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.

Gastrointestinal Cancer

Masanori Terashima, MD, PhD, on Gastric Cancer: Results of the JCOG1001 Trial

Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).

Gastrointestinal Cancer

Salah-Eddin Al-Batran, MD, on Gastric Cancer: RADPAC Trial Results

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses study findings on paclitaxel with and without RAD001 in patients with gastric cancer whose disease has progressed after therapy with a fluoropyrimidine/platinum-containing regimen (Abstract 4).

Pancreatic Cancer
Hepatobiliary Cancer

Eileen M. O’Reilly, MD, on Pancreatic and Hepatobiliary Cancers: Selecting High-Impact Targets

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.

Advertisement

Advertisement




Advertisement